Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

398 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types.
Brown LC, Tucker MD, Sedhom R, Schwartz EB, Zhu J, Kao C, Labriola MK, Gupta RT, Marin D, Wu Y, Gupta S, Zhang T, Harrison MR, George DJ, Alva A, Antonarakis ES, Armstrong AJ. Brown LC, et al. Among authors: antonarakis es. J Immunother Cancer. 2021 Mar;9(3):e001792. doi: 10.1136/jitc-2020-001792. J Immunother Cancer. 2021. PMID: 33653800 Free PMC article.
Targeting the spectrum of immune checkpoints in prostate cancer.
Sena LA, Denmeade SR, Antonarakis ES. Sena LA, et al. Among authors: antonarakis es. Expert Rev Clin Pharmacol. 2021 Oct;14(10):1253-1266. doi: 10.1080/17512433.2021.1949287. Epub 2021 Jul 15. Expert Rev Clin Pharmacol. 2021. PMID: 34263692 Free PMC article. Review.
Extreme Responses to a Combination of DNA-Damaging Therapy and Immunotherapy in CDK12-Altered Metastatic Castration-Resistant Prostate Cancer: A Potential Therapeutic Vulnerability.
Gongora ABL, Marshall CH, Velho PI, Lopes CDH, Marin JF, Camargo AA, Bastos DA, Antonarakis ES. Gongora ABL, et al. Among authors: antonarakis es. Clin Genitourin Cancer. 2022 Apr;20(2):183-188. doi: 10.1016/j.clgc.2021.11.015. Epub 2021 Dec 24. Clin Genitourin Cancer. 2022. PMID: 35027313 No abstract available.
Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies.
Zurita AJ, Graf RP, Villacampa G, Raskina K, Sokol E, Jin D, Antonarakis ES, Li G, Huang RSP, Casanova-Salas I, Vivancos A, Carles J, Ross JS, Schrock AB, Oxnard GR, Mateo J. Zurita AJ, et al. Among authors: antonarakis es. JCO Precis Oncol. 2022 Jul;6:e2200195. doi: 10.1200/PO.22.00195. JCO Precis Oncol. 2022. PMID: 35820087 Free PMC article.
398 results